Geng Z, et al. - To estimate the relative risk (RR) of respiratory adverse events (AEs) among individuals with rheumatoid arthritis (RA) treated with tocilizumab (TCZ), researchers evaluated the data in this randomized controlled trial (RCT). Using random-effects or fixed-effects models based on the heterogeneity, they calculated the RR of infectious and non-infectious respiratory AEs and severe AEs (SAEs). They found an association of TCZ with a higher risk of infectious respiratory AEs in relation to comparator agents but was not found correlated with an increased risk of non-infectious respiratory AEs. They noted comparable consequences for non-infectious AEs and SAEs while comparing TCZ with MTX and adalimumab (ADA). But an association was recorded with increased risks of these AEs, not with SAEs when compared with the placebo (PBO).